Ala F Nassar, PhD
Senior Research ScientistCards
About
Research
Overview
Our research focuses on understanding how structure modification can improve the ADME-Tox profile for new chemical entities as they advance toward clinical candidacy. Our recent efforts use Mass Cytometry & MALDI-IHC as novel tools for Cancer Research. With their capacity for tremendous detail, these techniques produce enhanced investigative power for analyses involving simultaneous cellular profiling of multiple cell populations. Our latest endeavors are focused on an advance in single cell analysis using a hybrid mass spectrometry-flow cytometry instrument to identify and characterize rare cell types in clinical samples. Another emphasis is the development of mass spectrometric and proteomic methods for application in biological and clinical contexts to identify and quantify proteins with greater depth and coverage in a single cell.
Medical Subject Headings (MeSH)
Academic Achievements & Community Involvement
News & Links
Media
- Photo by Bendall SC, et al. Trends Immunol. 2012;33:323–332.
A liquid sample containing cells labeled with heavy metal isotope-conjugated probes (ICPs) (a) is introduced into the nebulizer (b), where it is aerosolized. The aerosol droplets are directed into the ICP torch (c),
where the cells are vaporized, atomized, and ionized. Low-mass ions are
removed in the radiofrequency (RF) quadrupole ion guide (d), resulting in a cloud of ions enriched for the probe isotopes. The ion cloud then enters the time-of-flight (TOF) chamber (e),
where the ions are separated on the basis of their mass:charge ratio as
they accelerate toward the detector. Thus, the time-resolved detector
measures a mass spectrum (f) that represents the identity and quantity of each isotope on a per cell basis. Data are generated in .fcs format (g) and analyzed using the cloud-based Cytobank platform (h).